Perimenopause, Depression
Conditions
Brief summary
Main objective: to compare the effects of electro-acupuncture and escitalopram oxalate tablets on mild-to-moderate perimenopausal depression, and to evaluate the safety of electroacupuncture stimulation.
Interventions
DEVICEelectro-acupuncture
8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang. Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\ 1.0 mA
escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
Sponsors
Guangdong Provincial Hospital of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Conforms to the diagnosis standard of STRAW-10 for perimenopause, conforms to the diagnosis standard of The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for depression, and conforms to the diagnosis standard of The International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) F32.0(mild depression) or F32.1(moderate depression); * Fisrt attack during perimenopausal period; * HAMD-17 score \>7 and \<23; * Age ≥45 to ≤55; * No hormone replacement therapy (HRT) or no antidepressant 3 months before into the group; * Sign the consent consent, volunteered for this study
Exclusion criteria
* Fail to rule out the possibility of suicide in depression factor of The Symptom Checklist (SCL-90); * Application of estrogen, progesterone, selective serotonin reuptake inhibitors (SSRIs), soybean isoflavone, vitamin E or black cohosh in recent 4 weeks; * Allergic to citalopram or escitalopram tablets; * Taken the non selective, irreversible inhibitor of monoamine oxidase (MAOIs) in recent 2 weeks; * Taken linezolid, pimozide, tryptophane,tramadol, triptans or other drugs that may cause drug adverse reactions in recent 2 weeks; * Patient with prolongation of the QT interval or congenital long QT syndrome * Taken herbs or products that contain isatin, pilose antler, hawthorn, fleeceflower root, common St.John's wort herb, hypericin; * Ovarian dropsy or hysteromyoma with more than 4cm diameter, oophorectomy, or hysterectomy; * Mandatory indications of hormonotherapy, such as surgery-induced menopause or osteoporosis; * Patient with history of radiotherapy or chemotherapy, or undergoing radiotherapy or chemotherapy; * Vaginal bleeding of undetermined origin; * Patient with coagulation disorders, or taking anticoagulants such as Warfarin, or heparin; * Patient with skin diseases, such as eczema,or psoriasis; * Serious hepatic insufficiency or serious renal inadequacy; * Uncontrolled hypertension, diabetes, or thyroid disease; * Diabetic neuropathy, or malignant tumor; * Pregnancy intention, in pregnancy or lactation; * Regular use of sedative and anti anxiety drugs; * The long-term smoking and/or drinking; * Having Pacemaker or artificial joint； * Electrolyte is disorder, serious heart disease or other potential life-threatening disease patients; * Compliance may be poor or fear of acupuncture.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in scores of the 17-item Hamilton depression rating scale (HAMD-17) | 0 week, 4th week, 8th week, 12th week, 16th week and 24th week |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in scores of the Menopause-Specific Quality of Life questionnaire (MENQOL) | 0 week, 4th week, 8th week, 12th week, 16th week, 20th week and 24th week |
| Change from Baseline in level of estradiol (E2), | 0 week, 12th week |
| Change from Baseline in level of follicle-stimulating hormone (FSH) | 0 week, 12th week |
| Change from baseline in level of Luteinizing hormone (LH) | 0 week, 12th week |
| Change from baseline in level of FSH/LH | 0 week, 12th week |
Other
| Measure | Time frame | Description |
|---|---|---|
| safety of electro-acupuncture as measured by safety and acceptability questionnaires | 0 week, 4th week, 8th week, and 12th week | safety and acceptability |
| safety of both groups before treatment as measured by urine regular test | 0 week | Urine regular test |
| safety of escitalopram as measured by Asberg Rating Scale for Side Effect (SERS) | 0 week, 4th week, 8th week, and 12the week | Asberg Rating Scale for Side Effect (SERS) |
| safety of escitalopram as measured by liver functure test | 0 week, 4th week, 8th week, and 12the week | ALT, aspartate transminase (AST), and TBIL |
| safety of escitalopram as measured by kidney functure test | 0 week, 4th week, 8th week, and 12the week | Cr, BUN |
| safety of both groups before treatment as measured by EKG | 0 week | EKG |
| safety of both groups before treatment as meausred by blood regular test | 0 week | Blood regular test |
Countries
China
Contacts
Primary ContactWenbin Fu, MD
Backup ContactZhaofeng Li
Outcome results
None listed